Cervical Intraepithelial Neoplasia Drug Pipeline Research Report 2023 Featuring Inovio Pharmaceuticals, Frantz Viral Therapeutics, Antiva Biosciences, Genexine, and Merck Sharp & Dohme – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cervical Intraepithelial Neoplasia – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com’s offering.

This report report offers a comprehensive analysis of the current landscape and future growth prospects in the field of Cervical Intraepithelial Neoplasia.

This report provides a detailed overview of the pipeline for Cervical Intraepithelial Neoplasia, including profiles of over 8 companies and 10 pipeline drugs. It covers both clinical and nonclinical stage products and provides insights into the therapeutics assessment based on product type, stage, route of administration, and molecule type.

Additionally, the report highlights inactive pipeline products in this area. With a focus on the present scenario and future potential, this report serves as a valuable resource for understanding the Cervical Intraepithelial Neoplasia pipeline landscape, including disease overview and treatment guidelines.

Furthermore, it includes a comprehensive assessment of the commercial and clinical aspects of the pipeline products, offering detailed descriptions of drug mechanisms, clinical studies, NDA approvals, and product development activities such as collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.

This report showcases the dedication of companies and academics in addressing the challenges and opportunities in Cervical Intraepithelial Neoplasia research and development, focusing on novel approaches to improve the treatment and management of this condition.

Cervical Intraepithelial Neoplasia Emerging Drugs Chapters

This segment of the Cervical Intraepithelial Neoplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cervical Intraepithelial Neoplasia Emerging Drugs

VGX-3100: Inovio Pharmaceuticals

INOVIO’s product candidate VGX-3100 is designed to significantly increase T cell immune responses against the E6 and E7 antigens of HPV types 16 and 18 that are present in both precancerous and cancerous cells transformed by these HPV types.

INOVIO’s lead candidate VGX-3100, currently in Phase III trials for precancerous cervical dysplasia. In the Phase IIb clinical trial the drug demonstrated that it had eliminated high grade dysplasia in nearly 50% of women; in 80% of those whose high grade dysplasia was eliminated, the HPV infection was also cleared by VGX-3100.

Artesunate: Frantz Viral Therapeutics

Artesunate is a derivative of artemisinin. The drug is self-administered via vaginal inserts (similar to yeast infection treatment), anal suppositories, or as an ointment for pre-cancers of cervical, perianal and vulvar/vaginal tissues respectively.

The safe and effective Phase I study of artesunate for the treatment of CIN results are published in Gynecologic Oncology, the journal of the Society of Gynecologic Oncology: A First-in Human Proof-of Concept Trial of Intravaginal Artesunate and were found safe and well-tolerated, at clinically effective doses to treat CIN. Currently, the drug is being evaluated in the Phase II stage of development.

Cervical Intraepithelial Neoplasia: Therapeutic Assessment

This segment of the report provides insights about the different Cervical Intraepithelial Neoplasia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cervical Intraepithelial Neoplasia

There are approx. 8+ key companies which are developing the therapies for Cervical Intraepithelial Neoplasia. The companies which have their Cervical Intraepithelial Neoplasia drug candidates in the most advanced stage, i.e. phase III include, Inovio Pharmaceuticals.

Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Cervical Intraepithelial Neoplasia Report Insights

• Cervical Intraepithelial Neoplasia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cervical Intraepithelial Neoplasia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Players

• Inovio Pharmaceuticals
• Frantz Viral Therapeutics
• Antiva Biosciences
• Genexine, Inc.
• Merck sharp & Dohme

Key Products

• VGX-3100
• Artesunate
• ABI-2280
• GX-188E
• Pembrolizumab

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/79o1qm

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900